Product Information
RIZATRIPTAN 5 MG ODT is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.5446 per EA under NDC 33342009341. Its NADAC has been published 404 times since Jan 9, 2019.
FDA first approved this application on Sep 19, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342009341
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIZATRIPTAN BENZOATEApproval Type
Generic (ANDA)
FDA Application
ANDA203146FDA Approved
9/19/2014
TE Code
AB
On Market Since
9/23/2014
Pharmacological Classes
Price Statistics
The NADAC for RIZATRIPTAN 5 MG ODT has been published 404 times since Jan 9, 2019, and over the history we have for it it has declined 43.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5446 per EA |
|---|---|
| All-time high | $1.3658 (Dec 16, 2020) |
| All-time low | $0.4078 (Jul 17, 2024) |
| 52-week high | $0.5745 |
| 52-week low | $0.4842 |
| Median price | $0.7483 |
| Average price | $0.7971 |
| Largest weekly change | +69.8% (Aug 21, 2024) |
| Weeks tracked | 404 |
| Tracking since | Jan 9, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 5% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rizatriptan benzoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIZATRIPTAN 5 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for RIZATRIPTAN 5 MG ODT, manufactured by Macleods Pharmaceuticals Limited, is $0.5446 per EA (NDC 33342009341), effective Sep 30, 2026.
How has the price of RIZATRIPTAN 5 MG ODT changed over time?
Over the history we have for it, the NADAC for RIZATRIPTAN 5 MG ODT has declined 43.7%. It has been tracked across 404 weekly CMS publications since Jan 9, 2019.
What are the highest and lowest recorded NADAC prices for RIZATRIPTAN 5 MG ODT?
Since Jan 9, 2019, the NADAC for RIZATRIPTAN 5 MG ODT has ranged from a low of $0.4078 (Jul 17, 2024) to a high of $1.3658 (Dec 16, 2020), with a median of $0.7483 per EA.
Are there cheaper alternatives to RIZATRIPTAN 5 MG ODT?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RIZATRIPTAN 5 MG TABLET, is $0.5163 per EA — about 5% below RIZATRIPTAN 5 MG ODT.
Who manufactures RIZATRIPTAN 5 MG ODT?
RIZATRIPTAN 5 MG ODT (NDC 33342009341) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.